Rivaroxaban
Rivaroxaban
Rivaroxaban is the active pharmaceutical ingredient of Xarelto®.
Xarelto® is the first direct oral Factor Xa inhibitor (approved in the European Union for the prevention of venous thromboembolism [VTE] in adult patients undergoing elective hip or knee replacement surgery), a new generation of investigational anticoagulants targeting the prevention and treatment of acute and chronic thromboembolic diseases. Extensive studies already involve more than 32,000 patients, and more than 60,000 patients are expected to be evaluated when the studies are completed. This establishes Xarelto® as the most studied anticoagulant of its kind to date.64, 68
Xarelto® is the first direct oral Factor Xa inhibitor (approved in the European Union for the prevention of venous thromboembolism [VTE] in adult patients undergoing elective hip or knee replacement surgery), a new generation of investigational anticoagulants targeting the prevention and treatment of acute and chronic thromboembolic diseases. Extensive studies already involve more than 32,000 patients, and more than 60,000 patients are expected to be evaluated when the studies are completed. This establishes Xarelto® as the most studied anticoagulant of its kind to date.64, 68
See also: Oral Anticoagulant
- 64 - Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S. [press release] Available at http://www.viva.vita.bayerhealthcare.com/index.php?id=36&tx_ttnews[tt_news]=12625&cHash=97a2ea4a90
- 68 - U.S. FDA Advisory Committee supports favorable benefit-risk profile of Bayer’s rivaroxaban [press release] Available at http://www.press.bayer.com/baynews/baynews.nsf/id/2A95822BEA3213E7C125757E0074EC47?Open
